EUVIMEDEUVIMED entdecken
Editorial

Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Praful Ravi, Bridget Whelpley, Emma Kelly, Andrew Wolanski, Jolivette Ritzer, Matthew Robertson, Hina Shah, Alicia K Morgans, Xiao X Wei, Rajitha Sunkara, Mark Pomerantz, Mary-Ellen Taplin und 3 weitere

Journal of Nuclear Medicine · 2023-03 · 64 (3) · 349-350

DOI: 10.2967/jnumed.122.265194 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.01.2023. Verfasst von Praful Ravi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, Massachusetts; and praful_ravi@dfci.harvard.edu. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In March 2022, 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan) received Food and Drug Administration approval for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men with prostate-specific membrane antigen (PSMA)–avid disease who have received prior chemotherapy and a novel

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansUnited StatesDipeptidesHeterocyclic Compounds, 1-RingLongitudinal StudiesLutetium

Substanzen

PSMA-617Prostate-Specific AntigenDipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, Massachusetts; and praful_ravi@dfci.harvard.edu.
  • Dana-Farber Cancer Institute, Boston, Massachusetts; and.
  • Brigham and Women's Hospital, Boston, Massachusetts.

Zitieren

APA

Ravi, P., Whelpley, B., Kelly, E., Wolanski, A., Ritzer, J., Robertson, M., Shah, H., Morgans, A. K., Wei, X. X., Sunkara, R., Pomerantz, M., Taplin, M. E., Kilbridge, K. L., Choudhury, A. D., & Jacene, H. (2023). Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. Journal of Nuclear Medicine, 64(3), 349-350. https://doi.org/10.2967/jnumed.122.265194

Vancouver

Ravi P, Whelpley B, Kelly E, Wolanski A, Ritzer J, Robertson M, et al. Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. Journal of Nuclear Medicine. 2023;64(3):349-350. doi:10.2967/jnumed.122.265194

BibTeX
@article{Ravi2023,
  author = {Ravi, Praful and Whelpley, Bridget and Kelly, Emma and Wolanski, Andrew and Ritzer, Jolivette and Robertson, Matthew and Shah, Hina and Morgans, Alicia K and Wei, Xiao X and Sunkara, Rajitha and Pomerantz, Mark and Taplin, Mary-Ellen and Kilbridge, Kerry L and Choudhury, Atish D and Jacene, Heather},
  title = {Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {3},
  pages = {349--350},
  doi = {10.2967/jnumed.122.265194}
}
Kostenlos starten →